WO1991015194A1 - Taste masking of ibuprofen by fluid bed coating - Google Patents
Taste masking of ibuprofen by fluid bed coating Download PDFInfo
- Publication number
- WO1991015194A1 WO1991015194A1 PCT/US1991/001089 US9101089W WO9115194A1 WO 1991015194 A1 WO1991015194 A1 WO 1991015194A1 US 9101089 W US9101089 W US 9101089W WO 9115194 A1 WO9115194 A1 WO 9115194A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ibuprofen
- composition according
- plasticizer
- chewable
- coating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- Ibuprofen is a well-known therapeutic agent. Its therapeutic activities include analgesia and anti-pyretic attack. As with most medicines, one of the difficulties with ibuprofen is in making it palatable to children. This difficulty has been overcome with most medicines by preparing formulations such as syrups and drops.
- the present invention relates to chewable tablets that are palatable to children and a process for making the tablets.
- Ibuprofen and its use for treatment of analgesia is disclosed in U.S. patent 3,385,886.
- Compositions containing ibuprofen and methods for using them are described in U.S. patent 3,228,831.
- New crystalline and high dose formulations of ibuprofen are disclosed in U.S. patents 4,476,248 and 4,609,675 respectively.
- Microencapsulation is described by J.A. Bakan, Part Three of "The Theory and
- EUDRAGIT L30D is a known polymer useful for coating orally administered pharmaceutical dosage forms, particularly tablets, capsules and pills, with coatings which are resistant to gastric juices but solvent in intestinal juices.
- Chewable taste-masked pharmaceutical compositions, including some containing ibuprofen, are described in U.S. patent 4,800,087. However, the compositions described therein require a coating consisting of a mixture of polymers. The use of fluidized bed for coating pharmaceutical products is described in U.S. Patent 4,800,087.
- a chewable taste-masked tablet having controlled release characteristics comprising a microcapsule of about 100 microns to about 0.8 mm in diameter having (a) a pharmaceutical core including crystalline ibuprofen and (b) a methacrylic acid copolymer coating having sufficient elasticity to withstand chewing.
- the present invention comprises formulations of taste-masked microcapsules which further comprise (a) a pharmaceutical core of crystalline ibuprofen and (b) a methacrylic acid copolymer coating that may provide chewable taste-masked characteris- tics.
- Both the polymeric coating and the pharmaceutical core may further comprise diluents, fillers and other pharmaceutical additives which may effect the rate pf release of active ibuprofen from the microcapsule.
- the methacrylic acid copolymer is preferably dispersable in water so as to take advantage of aqueous formulation techniques and has a rapid rate of dissolution at a pH of about 5.5.
- Aqueous-based coating systems are safe and make regulatory compliance (EPA) relatively easy compared to non-aquaous based coating systems.
- An elastic microcapsule which will not release ibuprofen in the mouth when chewed is contemplated by the present invention.
- a preferred coating composition is a high temperature film forming polymer or "hard" polymer.
- a hard polymer is defined as a polymer that will form a film on a pharmaceutical core at a temperature of at least about 30°C.
- high temperature film forming polymers useful in this invention include hydroxypropylmethyl cellulose, for example, Pharmacoat' 606 brand from Shinetro Corp., Tokyo, Japan, hydroxypropyl cellulose, for example, Klucel' brand from Hercules Corp., Wilmington, Del. , methylcellulose for example Methocel A% from Dow Chemical, Midland, Mich.
- ethylcellulose for example, Ethocel' brand from Dow Chemical Corp., and other aqueous polymeric dispersions such as Aquacost' Brand from FMC, Philadelphia, PA., and Surelease' brand from Colorcon, West Point, PA., polyvinyl alcohol, polyvinyl acetate, cellulose acetate butyrate, styrene acylate copolymers, for example Janocryl 138 (61 °C. film forming copolymer from S.C. Johnson, Racine, Wis.) and copolymers of acrylic acid esters, for example, the EUDRAGIT Copolymers (Rohm Phar a GmbH Westerstadt, W. Germany): Eudragit' L30D, Eudragit' L100-55, Eudragit' RS(30D and 100).
- EUDRAGIT Copolymers Roshm Phar a GmbH Westerstadt, W. Germany
- Eudragit' copolymers that are preferred in embodiments of this invention include L30D, an anionic copolymer based of polymethacrylic and acrylic acid esters (Methacrylic Acid Copolymer, Type C in USP XX-L/NF XVI) with a mean molecular weight of 250,000.
- the polymeric coating should provide for immediate release characteristics, i.e. , rapid release of the active agents in the duodenum within a period of about one hour.
- the microcapsules are formulated into chewable, taste-masked oral tablets or capsules, the formulations provide for immediate, rapid release in the stomach.
- the chewable polymeric coating providing immediate release upon reaching the duodenum i.e. , within one hour after ingestion may be comprised of a pharmaceutically compatible high temperature film forming polymer that is water insoluble or not swellable within thepH range (about 5.5-6.5) and or the liquid content of the mouth and will not release the active agent in the mouth, but will dissolve or change in physical character in the duodenum, for example, swell or become more porous, thus releasing drug.
- EUDRAGIT L30D The most preferred film forming acrylic resin polymer that releases active agent rapidly in duodenum is EUDRAGIT L30D.
- EUDRAGIT L30D is a copolymer anionic in character, based on polymethacrylic acid and acrylic acid esters.
- EUDRAGIT L30D is soluble at pH's in the mouth and insoluble at pH's of the stomach, it has found usefulness in chewable, taste-masked immediate release formulations of the present invention. This usefulness may stem from the lack of liquid in the mouth, or may be the result of elastic qualities that EUDRAGIT L30D acquires when formulated in combination with a plasticizer, or preferably, with EUDRAGIT E30D.
- plasticizers may be incorporated into the coatings.
- Plasticizers useful to provide the requisite elasticity include propylene glycol and polyalkylene glycols, for example, polyethylene glycol, triacetin, (glyceryl triacetate from Eastman Kodak, Rochester, NY vinyl pyrrolidone, diethyl phthallate, dibutylsebacate, and esters of citric acid among others.
- the plasticizers comprise between about 2% and about 50% by weight of polymer and plasticizer combined, preferably between about 5% and 15% by weight and most preferably about 10% by weight of the polymer and plasticizer combined.
- the chewable tablets of this invention are prepared by spraying a solution of the methacrylic acid copolymer on to a fluidized bed of crystalline ibuprofen.
- Crystalline ibuprofen can be prepared by the process described in U.S. Patent 4,476,248.
- the particle size of the ibuprofen should be about 80 to 500 microns and it it may contain excipients such as starch, lactose, hydroxypropyl methylcellulose, microcrystalline cellulose PVP, sucrose and fructose.
- the residence time should be such that the ratio of copolymer to ibuprofen of each chewable tablet is about eight percent by weight.
- the temperature of the inlet and outlet air should be maintained between 40 and 60 C. 20 and 40 C. respectively.
- the preferred inlet and outlet air temperatures are between 45 and 55 and 33 and 27°C respectively.
- the temperature of the fluidized bed should be maintained between 60 and 20 p respectively.
- the preferred temperature of the bed is about 35 C.
- the amount of ENDRAGIT L30D in the encapsulation formulation should be between about 10% to 60% by weight of ibuprofen, preferably about 14%.
- Ibuprofen crystals (particle size #40-105) are air suspended in a closed chamber (Glatt GPCG5).
- An aqueous dispersion of Eudragit L 30D and talc is sprayed onto the fluidized bed of ibuprofen at a rate of 60gm/min.
- the inlet and outlet air temperature are maintained at 50°C. and 20-22°C. respectively.
- the air rate is adjusted so as to maintain the particles in a suspended state and to maintain the fluidized bed at a tempera ⁇ ture of 35 °C.
- Table 1 shows a comparison of dissolution data between MOTRIN IB Tablet in PH 7.2 and the MOTRIN Chewable Tablets of this invention.
- Table 2 shows a comparison of dissolution data between MOTRIN IB Tablets in and the MOTRIN Chewable Tablets of this invention.
- Formula #12, #13 and Motrin IB shows the same reline forte after 10 minutes.
- Formula #12, #13 all pass U.S. P. Tablets specification 20 minutes 785%.
- Flask 1 Motrin IB.
- Flask 2 Motrin chewable experiment Lot 12.
- Flask 3 Motrin chewable experiment Lot 13.
- Flask 4 Recrystallized Ibuprofen.
- Flask 1 Motrin IB.
- Flask 2 Motrin chewable experiment Lot 12.
- Flask 3 Motrin chewable experiment Lot 13.
- Flask 4 Recrystallized Ibuprofen.
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU5053248A RU2101010C1 (en) | 1990-04-11 | 1991-02-26 | Taste ibuprofen masking with polymer coating |
JP91504575A JPH05506011A (en) | 1990-04-11 | 1991-02-26 | Taste masking of ibuprofen by fluidized bed coating |
EP91904188A EP0524180B1 (en) | 1990-04-11 | 1991-02-26 | Taste masking of ibuprofen by fluid bed coating |
DE69109282T DE69109282T2 (en) | 1990-04-11 | 1991-02-26 | METHOD FOR FLAVORING IBUPROFEN. |
NO923947A NO300758B1 (en) | 1990-04-11 | 1992-10-09 | Process for the preparation of a chewable, flavor-masked tablet having controlled release properties |
FI924589A FI924589A0 (en) | 1990-04-11 | 1992-10-09 | SMAKMASKERING AV IBUPROFEN MED VIRVELBAEDDBETAECKNING |
US08/469,715 US5552152A (en) | 1990-04-11 | 1995-06-06 | Taste masking of ibuprofen by fluid bed coating |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50819390A | 1990-04-11 | 1990-04-11 | |
US508,193 | 1990-04-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991015194A1 true WO1991015194A1 (en) | 1991-10-17 |
Family
ID=24021750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1991/001089 WO1991015194A1 (en) | 1990-04-11 | 1991-02-26 | Taste masking of ibuprofen by fluid bed coating |
Country Status (14)
Country | Link |
---|---|
US (1) | US5552152A (en) |
EP (1) | EP0524180B1 (en) |
JP (1) | JPH05506011A (en) |
AT (1) | ATE121619T1 (en) |
AU (1) | AU639988B2 (en) |
CA (1) | CA2076983A1 (en) |
DE (1) | DE69109282T2 (en) |
DK (1) | DK0524180T3 (en) |
ES (1) | ES2071986T3 (en) |
FI (1) | FI924589A0 (en) |
HU (2) | HUT64220A (en) |
NO (1) | NO300758B1 (en) |
RU (1) | RU2101010C1 (en) |
WO (1) | WO1991015194A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2785539A1 (en) * | 1998-11-06 | 2000-05-12 | Prographarm Laboratoires | PARTICLES COATED WITH GRANULAR CRYSTALLINE IBUPROFEN |
FR2785538A1 (en) * | 1998-11-06 | 2000-05-12 | Prographarm Laboratoires | PERFECTED QUICK DELIVERY TABLET |
WO2001012161A1 (en) * | 1999-08-17 | 2001-02-22 | Novartis Consumer Health S.A. | Rapidly dissolving dosage form and process for making same |
US8124124B2 (en) | 1999-12-09 | 2012-02-28 | Reckitt Benckiser Healthcare (Uk) Limited | Compressed tablet formulation comprising non-steroidal anti-inflammatory drugs and methods |
US8617587B2 (en) | 2002-03-11 | 2013-12-31 | Novartis Ag | Tasted masked veterinary solid compositions |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19648576C2 (en) * | 1996-11-23 | 1999-08-12 | Lohmann Therapie Syst Lts | Lozenge for modified release of active substances in the gastrointestinal tract |
FR2766089B1 (en) * | 1997-07-21 | 2000-06-02 | Prographarm Lab | IMPROVED MULTIPARTICULAR TABLET WITH RAPID DELIVERY |
CN1123573C (en) * | 1997-11-12 | 2003-10-08 | 拜尔公司 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
US6270807B1 (en) | 1999-03-02 | 2001-08-07 | L. Perrigo Company | Taste-masked pharmaceutical composition |
BR0009557A (en) | 1999-04-06 | 2002-05-28 | Ethypharm Lab Prod Ethiques | Pharmaceutical suspension for ibuprofen drinking |
EP1276470B1 (en) | 2000-04-20 | 2007-05-02 | Novartis AG | Taste masking coating composition |
US6551617B1 (en) | 2000-04-20 | 2003-04-22 | Bristol-Myers Squibb Company | Taste masking coating composition |
ES2278927T3 (en) * | 2001-05-09 | 2007-08-16 | Bayer Healthcare Ag | NEW USE OF IMIDAZOTRIAZINONES 2- (2-ETOXI-5- (4-METHYL-PIPERAZIN-1-SULPHONYL) -PHENYL) -5-METHYL-7-PROPIL-3H-IMIDAZO (5,1-F) (1, 2,4) TRIAZIN-4-ONA. |
ATE424812T1 (en) * | 2001-08-01 | 2009-03-15 | Novartis Ag | COMPOSITION FOR TASTE MASKING |
US20190328679A1 (en) | 2001-10-12 | 2019-10-31 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
DK1476138T3 (en) | 2002-02-21 | 2012-02-20 | Valeant Internat Barbados Srl | Modified release formulations of at least one form of tramadol |
DE10232113A1 (en) | 2002-07-16 | 2004-01-29 | Bayer Ag | Medicinal products containing vardenafil hydrochloride trihydrate |
FR2850275B1 (en) | 2003-01-24 | 2005-04-08 | Scherer Technologies Inc R P | SOFT MACHINE CAPSULES CONTAINING AN ACTIVE ACTIVE SUBSTANCE WITH MASK TASTE |
JP2007031281A (en) * | 2003-06-25 | 2007-02-08 | Kowa Co | Ibuprofen-containing film-coated tablet |
US20050220825A1 (en) * | 2004-03-10 | 2005-10-06 | Adrian Funke | Molecular dispersions of drospirenone |
DE102004023069A1 (en) * | 2004-05-11 | 2005-12-08 | Bayer Healthcare Ag | New dosage forms of the PDE 5 inhibitor vardenafil |
DE102005001989A1 (en) * | 2005-01-15 | 2006-07-20 | Bayer Healthcare Ag | Intravenous formulations of PDE inhibitors |
DE102005009240A1 (en) * | 2005-03-01 | 2006-09-07 | Bayer Healthcare Ag | Dosage forms with improved pharmacokinetic properties |
DE102005009241A1 (en) * | 2005-03-01 | 2006-09-07 | Bayer Healthcare Ag | Dosage forms with controlled bioavailability |
US20090186896A1 (en) * | 2005-09-29 | 2009-07-23 | Bayer Healthcare Ag | PDE Inhibitors and Combinations Thereof for the Treatment of Urological Disorders |
US20070134493A1 (en) * | 2005-12-08 | 2007-06-14 | Kanji Meghpara | Compositions and capsules with stable hydrophilic layers |
US7767248B2 (en) * | 2007-02-02 | 2010-08-03 | Overly Iii Harry J | Soft chew confectionary with high fiber and sugar content and method for making same |
EP2167057A1 (en) * | 2007-06-13 | 2010-03-31 | Bayer HealthCare AG | Pde inhibitors for the treatment of hearing impairment |
US8404275B2 (en) * | 2007-07-01 | 2013-03-26 | Vitalis Llc | Combination tablet with chewable outer layer |
EP2170051A1 (en) * | 2007-07-01 | 2010-04-07 | Joseph Peter Habboushe | Combination tablet with chewable outer layer |
ES2363964B1 (en) | 2009-11-20 | 2012-08-22 | Gp Pharm, S.A. | CAPSULES OF PHARMACEUTICAL ACTIVE PRINCIPLES AND ESTERS OF POLYINSATURATED FATTY ACIDS. |
US9149959B2 (en) | 2010-10-22 | 2015-10-06 | Monosol Rx, Llc | Manufacturing of small film strips |
US9226891B2 (en) | 2011-10-28 | 2016-01-05 | Vitalis Llc | Anti-flush compositions |
WO2013151754A1 (en) * | 2012-04-02 | 2013-10-10 | Teikoku Pharma Usa, Inc. | Ibuprofen solid oral dosage composition comprising a methacrylic acid copolymer |
US8993041B2 (en) | 2012-10-15 | 2015-03-31 | New Jersey Institute Of Technology | Taste masked active pharmaceutical powder compositions and processes for making them |
WO2014194872A1 (en) | 2013-06-04 | 2014-12-11 | Zentiva, K.S. | Taste masking of water soluble drugs using poloxamers |
RU2576236C1 (en) * | 2014-08-22 | 2016-02-27 | Александр Александрович Кролевец | Method of producing antibiotic nanocapsules in agar-agar |
RU2577689C1 (en) * | 2014-08-26 | 2016-03-20 | Александр Александрович Кролевец | Method of producing antibiotic nanocapsules in agar-agar |
RU2578408C1 (en) * | 2014-09-10 | 2016-03-27 | Александр Александрович Кролевец | Method of producing nanocapsules of alkaloids |
CA3022840A1 (en) | 2016-05-05 | 2017-11-09 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
RU2688148C1 (en) * | 2016-05-10 | 2019-05-20 | Александр Александрович Кролевец | Method of producing ecocide nanocapsules in carrageenan |
CN110917165A (en) * | 2019-12-26 | 2020-03-27 | 北京鑫开元医药科技有限公司海南分公司 | Ibuprofen orally disintegrating tablet and preparation method thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0212747A2 (en) * | 1985-08-16 | 1987-03-04 | The Procter & Gamble Company | Drug particles having constant release and immediate release |
EP0212751A2 (en) * | 1985-08-29 | 1987-03-04 | FARMACEUTICI FORMENTI S.p.A. | Process for the microencapsulation of a medicament, medicament so prepared and pharmaceutical compositions comprising it |
US4835186A (en) * | 1987-06-15 | 1989-05-30 | American Home Products Corporation | Spray dried ibuprofen |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB971700A (en) * | 1961-02-02 | 1964-09-30 | Boots Pure Drug Co Ltd | Anti-Inflammatory Agents |
US4476248A (en) * | 1983-02-28 | 1984-10-09 | The Upjohn Company | Crystallization of ibuprofen |
US4609675A (en) * | 1984-08-17 | 1986-09-02 | The Upjohn Company | Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing |
US4800087A (en) * | 1986-11-24 | 1989-01-24 | Mehta Atul M | Taste-masked pharmaceutical compositions |
US5084278A (en) * | 1989-06-02 | 1992-01-28 | Nortec Development Associates, Inc. | Taste-masked pharmaceutical compositions |
-
1991
- 1991-02-26 RU SU5053248A patent/RU2101010C1/en active
- 1991-02-26 DE DE69109282T patent/DE69109282T2/en not_active Expired - Fee Related
- 1991-02-26 WO PCT/US1991/001089 patent/WO1991015194A1/en active IP Right Grant
- 1991-02-26 DK DK91904188.9T patent/DK0524180T3/en active
- 1991-02-26 CA CA002076983A patent/CA2076983A1/en not_active Abandoned
- 1991-02-26 HU HU9203193A patent/HUT64220A/en unknown
- 1991-02-26 EP EP91904188A patent/EP0524180B1/en not_active Expired - Lifetime
- 1991-02-26 AU AU72560/91A patent/AU639988B2/en not_active Ceased
- 1991-02-26 ES ES91904188T patent/ES2071986T3/en not_active Expired - Lifetime
- 1991-02-26 JP JP91504575A patent/JPH05506011A/en active Pending
- 1991-02-26 AT AT91904188T patent/ATE121619T1/en not_active IP Right Cessation
-
1992
- 1992-10-09 FI FI924589A patent/FI924589A0/en not_active Application Discontinuation
- 1992-10-09 NO NO923947A patent/NO300758B1/en unknown
-
1995
- 1995-06-06 US US08/469,715 patent/US5552152A/en not_active Expired - Fee Related
- 1995-06-23 HU HU95P/P00418P patent/HU211247A9/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0212747A2 (en) * | 1985-08-16 | 1987-03-04 | The Procter & Gamble Company | Drug particles having constant release and immediate release |
EP0212751A2 (en) * | 1985-08-29 | 1987-03-04 | FARMACEUTICI FORMENTI S.p.A. | Process for the microencapsulation of a medicament, medicament so prepared and pharmaceutical compositions comprising it |
US4835186A (en) * | 1987-06-15 | 1989-05-30 | American Home Products Corporation | Spray dried ibuprofen |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2785539A1 (en) * | 1998-11-06 | 2000-05-12 | Prographarm Laboratoires | PARTICLES COATED WITH GRANULAR CRYSTALLINE IBUPROFEN |
FR2785538A1 (en) * | 1998-11-06 | 2000-05-12 | Prographarm Laboratoires | PERFECTED QUICK DELIVERY TABLET |
WO2000027357A1 (en) * | 1998-11-06 | 2000-05-18 | Laboratoires Des Produits Ethiques Ethypharm Sa | Improved fast disintegrating tablet |
WO2000027368A1 (en) * | 1998-11-06 | 2000-05-18 | Laboratoires Des Produits Ethiques Ethypharm Sa | Particles coated with granulated crystalline ibuprofen |
AU765765B2 (en) * | 1998-11-06 | 2003-09-25 | Ethypharm | Particles coated with granulated crystalline ibuprofen |
US6951657B1 (en) | 1998-11-06 | 2005-10-04 | Laboratoires Des Produits Ethiques Ethypharm Sa | Particles coated with granulated crystalline ibuprofen |
US7695735B2 (en) | 1998-11-06 | 2010-04-13 | Ethypharm | Fast disintegrating tablet |
WO2001012161A1 (en) * | 1999-08-17 | 2001-02-22 | Novartis Consumer Health S.A. | Rapidly dissolving dosage form and process for making same |
US7182959B2 (en) | 1999-08-17 | 2007-02-27 | Novartis Ag | Rapidly dissolving dosage form and process for making same |
US8124124B2 (en) | 1999-12-09 | 2012-02-28 | Reckitt Benckiser Healthcare (Uk) Limited | Compressed tablet formulation comprising non-steroidal anti-inflammatory drugs and methods |
US8617587B2 (en) | 2002-03-11 | 2013-12-31 | Novartis Ag | Tasted masked veterinary solid compositions |
Also Published As
Publication number | Publication date |
---|---|
EP0524180B1 (en) | 1995-04-26 |
DK0524180T3 (en) | 1995-09-04 |
NO923947L (en) | 1992-10-09 |
NO300758B1 (en) | 1997-07-21 |
DE69109282T2 (en) | 1995-09-28 |
FI924589A (en) | 1992-10-09 |
ES2071986T3 (en) | 1995-07-01 |
HUT64220A (en) | 1993-12-28 |
RU2101010C1 (en) | 1998-01-10 |
ATE121619T1 (en) | 1995-05-15 |
FI924589A0 (en) | 1992-10-09 |
DE69109282D1 (en) | 1995-06-01 |
JPH05506011A (en) | 1993-09-02 |
NO923947D0 (en) | 1992-10-09 |
US5552152A (en) | 1996-09-03 |
AU7256091A (en) | 1991-10-30 |
HU9203193D0 (en) | 1992-12-28 |
AU639988B2 (en) | 1993-08-12 |
EP0524180A1 (en) | 1993-01-27 |
HU211247A9 (en) | 1995-11-28 |
CA2076983A1 (en) | 1991-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5552152A (en) | Taste masking of ibuprofen by fluid bed coating | |
US5084278A (en) | Taste-masked pharmaceutical compositions | |
US4800087A (en) | Taste-masked pharmaceutical compositions | |
CA2137265C (en) | Palatable pharmaceutical compositions | |
US6576260B2 (en) | Sustained-release form of administration containing tramadol saccharinate | |
FI78835B (en) | FOERFARANDE FOER FRAMSTAELLNING AV EN NY DIPYRIDAMOL-RETARDFORM. | |
US5489436A (en) | Taste mask coatings for preparation of chewable pharmaceutical tablets | |
EP0524989B1 (en) | Controlled release drug formulation | |
US6270798B2 (en) | Lozenge for the modified releasing of active substances in the gastrointestinal tract | |
SK9899A3 (en) | Tramadol multiple unit formulations | |
WO1994028882A1 (en) | Multiparticulate pulsatile drug delivery system | |
JPH03112930A (en) | System for pulsating release once per day of minocycline | |
HRP20010198A2 (en) | Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same | |
US5837277A (en) | Palatable pharmaceutical compositions | |
WO2001010467A1 (en) | Solid preparations containing chitosan powder and process for producing the same | |
KR101436516B1 (en) | Dispersible tablet containing coated pellet and preparation method thereof | |
EP1235556A2 (en) | Taste masking coating compositions | |
KR100858631B1 (en) | Controlled release of Indapamide using pellet-tape dosage form | |
RU2292877C2 (en) | Medicinal retard-formulation containing tramadol saccharinate | |
WO1994007503A1 (en) | Enteric preparations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BB BG BR CA FI HU JP KP KR LK MC MG MW NO PL RO SD SU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1991904188 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2076983 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 924589 Country of ref document: FI |
|
WWP | Wipo information: published in national office |
Ref document number: 1991904188 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1991904188 Country of ref document: EP |